HC Wainwright Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

Viridian Therapeutics (NASDAQ:VRDN) had its price target upped by stock analysts at HC Wainwright from $22.00 to $40.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright‘s target price indicates a potential upside of 37.65% from the company’s current price.

Several other equities research analysts have also weighed in on VRDN. Royal Bank Of Canada upped their price objective on Viridian Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Tuesday, September 22nd. Truist Financial boosted their target price on Viridian Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Needham & Company LLC increased their price target on Viridian Therapeutics from $34.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday. Wall Street Zen cut shares of Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, October 4th. Finally, Weiss Ratings upgraded Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 14th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Viridian Therapeutics has an average rating of “Moderate Buy” and an average target price of $39.09.

Viridian Therapeutics Price Performance

Shares of VRDN opened at $29.06 on Thursday. The company has a current ratio of 16.95, a quick ratio of 16.95 and a debt-to-equity ratio of 0.43. The stock has a 50 day moving average of $21.80 and a 200-day moving average of $21.85. The firm has a market cap of $3.29 billion, a price-to-earnings ratio of -8.62 and a beta of 1.07. Viridian Therapeutics has a 52 week low of $13.18 and a 52 week high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.21. The firm had revenue of $25.75 million for the quarter, compared to analysts’ expectations of $4.72 million. Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%. As a group, analysts forecast that Viridian Therapeutics will post -4.07 EPS for the current year.

Insider Buying and Selling

In related news, insider Jennifer Tousignant sold 14,212 shares of Viridian Therapeutics stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total value of $348,194.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp increased its holdings in Viridian Therapeutics by 0.3% in the 1st quarter. Bank of New York Mellon Corp now owns 216,525 shares of the company’s stock worth $4,235,000 after buying an additional 659 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Viridian Therapeutics by 6.6% in the 3rd quarter. ProShare Advisors LLC now owns 12,609 shares of the company’s stock worth $260,000 after buying an additional 784 shares during the period. 71 West Capital Partners raised its position in shares of Viridian Therapeutics by 4.1% during the third quarter. 71 West Capital Partners now owns 22,282 shares of the company’s stock valued at $459,000 after buying an additional 882 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in Viridian Therapeutics by 13.5% during the third quarter. Pictet Asset Management Holding SA now owns 12,741 shares of the company’s stock valued at $262,000 after purchasing an additional 1,516 shares in the last quarter. Finally, KBC Group NV purchased a new stake in Viridian Therapeutics during the 1st quarter valued at $34,000.

Key Headlines Impacting Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Viridian reported a Q3 loss of $0.81 per share, narrower than analysts’ expected loss of $1.01–$1.02. Revenue of $25.75 million also exceeded the roughly $4.72 million consensus estimate. The EPS loss was nevertheless wider than the $0.34 loss a year earlier. Viridian Q3 results
• Positive Sentiment: Management signaled it is targeting a biologics license application for elegrobart in Q1 2027 and expects Lumvoa’s launch to reach broad coverage within six to nine months—milestones that could strengthen the commercial and pipeline outlook. Elegrobart and Lumvoa outlook
• Positive Sentiment: Needham raised its price target to $38 from $34 and maintained a Buy rating, reflecting a more optimistic analyst view of VRDN’s prospects. Needham price target update
• Negative Sentiment: A Yahoo Finance commentary said VRDN looks overvalued even with its new launch, highlighting valuation as a potential concern after the stock’s strong performance. Valuation commentary

About Viridian Therapeutics

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.